No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

Lara E Sucheston-Campbell; Rikki Cannioto; Alyssa I Clay; John Lewis Etter; Kevin H Eng; Song Liu; Sebastiano Battaglia; Qiang Hu; J Brian Szender; Albina Minlikeeva; Janine M Joseph; Paul Mayor; Scott I Abrams; Brahm H Segal; Paul K Wallace; Kah Teong Soh; Emese Zsiros; Hoda Anton-Culver; Elisa V Bandera; Matthias W Beckmann; Andrew Berchuck; Line Bjorge; Amanda Bruegl; Ian G Campbell; Shawn Patrice Campbell; Georgia Chenevix-Trench; Daniel W Cramer; Agnieszka Dansonka-Mieszkowska; Fanny Dao; Brenda Diergaarde; Thilo Doerk; Jennifer A Doherty; Andreas du Bois; Diana Eccles; Svend Aage Engelholm; Peter A Fasching; Simon A Gayther; Aleksandra Gentry-Maharaj; Rosalind M Glasspool; Marc T Goodman; Jacek Gronwald; Philipp Harter; Alexander Hein; Florian Heitz; Peter Hillemmanns; Claus Høgdall; Estrid V S Høgdall; Tomasz Huzarski; Allan Jensen; Sharon E Johnatty; Audrey Jung; Beth Y Karlan; Reudiger Klapdor; Tomasz Kluz; Bożena Konopka; Susanne Krüger Kjær; Jolanta Kupryjanczyk; Diether Lambrechts; Jenny Lester; Jan Lubiński; Douglas A Levine; Lene Lundvall; Valerie McGuire; Iain A McNeish; Usha Menon; Francesmary Modugno; Roberta B Ness; Sandra Orsulic; James Paul; Celeste Leigh Pearce; Tanja Pejovic; Paul Pharoah; Susan J Ramus; Joseph Rothstein; Mary Anne Rossing; Matthias Rübner; Joellen M Schildkraut; Barbara Schmalfeldt; Ira Schwaab; Nadeem Siddiqui; Weiva Sieh; Piotr Sobiczewski; Honglin Song; Kathryn L Terry; Els Van Nieuwenhuysen; Adriaan Vanderstichele; Ignace Vergote; Christine S Walsh; Penelope M Webb; Nicolas Wentzensen; Alice S Whittemore; Anna H Wu; Argyrios Ziogas; Kunle Odunsi; Jenny Chang-Claude; Ellen L Goode; Kirsten B Moysich; Australian Ovarian Cancer Study

doi:10.1158/1055-9965.EPI-16-0631

Back

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

Journal article

Open access

Peer reviewed

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

Lara E Sucheston-Campbell, Rikki Cannioto, Alyssa I Clay, John Lewis Etter, Kevin H Eng, Song Liu, Sebastiano Battaglia, Qiang Hu, J Brian Szender, Albina Minlikeeva, …

Cancer epidemiology, biomarkers & prevention, Vol.26(3), pp.420-424

03/2017

DOI: https://doi.org/10.1158/1055-9965.EPI-16-0631

PMCID: PMC5500198

PMID: 27677730

Abstract

Carcinoma, Ovarian Epithelial

Female

Genetic Association Studies

Genetic Variation

Humans

Myeloid-Derived Suppressor Cells - immunology

Neoplasms, Glandular and Epithelial - genetics

Neoplasms, Glandular and Epithelial - immunology

Neoplasms, Glandular and Epithelial - mortality

Ovarian Neoplasms - genetics

Ovarian Neoplasms - immunology

Ovarian Neoplasms - mortality

The precise mechanism by which the immune system is adversely affected in cancer patients remains poorly understood, but the accumulation of immunosuppressive/protumorigenic myeloid-derived suppressor cells (MDSCs) is thought to be a prominent mechanism contributing to immunologic tolerance of malignant cells in epithelial ovarian cancer (EOC). To this end, we hypothesized genetic variation in MDSC pathway genes would be associated with survival after EOC diagnoses. We measured the hazard of death due to EOC within 10 years of diagnosis, overall and by invasive subtype, attributable to SNPs in 24 genes relevant in the MDSC pathway in 10,751 women diagnosed with invasive EOC. Versatile Gene-based Association Study and the admixture likelihood method were used to test gene and pathway associations with survival. We did not identify individual SNPs that were significantly associated with survival after correction for multiple testing ( < 3.5 × 10 ), nor did we identify significant associations between the MDSC pathway overall, or the 24 individual genes and EOC survival. In this well-powered analysis, we observed no evidence that inherited variations in MDSC-associated SNPs, individual genes, or the collective genetic pathway contributed to EOC survival outcomes. Common inherited variation in genes relevant to MDSCs was not associated with survival in women diagnosed with invasive EOC. .

Files and links (1)

url

https://doi.org/10.1158/1055-9965.EPI-16-0631View

Version of Record (VoR) Open

Metrics

13 Record Views

2 Times Cited - Web of Science

See more details

Details

Title: No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival
Creators: Lara E Sucheston-Campbell - College of Pharmacy, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio
Rikki Cannioto - Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
Alyssa I Clay - Cancer Genetic Epidemiology, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota
John Lewis Etter - Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
Kevin H Eng - Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York
Song Liu - Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York
Sebastiano Battaglia - Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York
Qiang Hu - Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York
J Brian Szender - Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York
Albina Minlikeeva - Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
Janine M Joseph - Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York
Paul Mayor - Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York
Scott I Abrams - Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York
Brahm H Segal - Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York
Paul K Wallace - Department of Flow & Image Cytometry, Roswell Park Cancer Institute, Buffalo, New York
Kah Teong Soh - Department of Flow & Image Cytometry, Roswell Park Cancer Institute, Buffalo, New York
Emese Zsiros - Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York
Hoda Anton-Culver - Genetic Epidemiology Research Institute, School of Medicine, University of California Irvine, Irvine, California
Elisa V Bandera - Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Matthias W Beckmann - Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Andrew Berchuck - Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
Line Bjorge - Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway
Amanda Bruegl - Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon
Ian G Campbell - Department of Pathology, University of Melbourne, Parkville, Victoria, Australia
Shawn Patrice Campbell - Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon
Georgia Chenevix-Trench
Daniel W Cramer - Harvard T. H. Chan School of Public Health, Boston, Massachusetts
Agnieszka Dansonka-Mieszkowska - Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Fanny Dao - Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, NYU Langone Medical Center, New York, New York
Brenda Diergaarde - Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania
Thilo Doerk - Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Niedersachsen, Germany
Jennifer A Doherty - Department of Epidemiology, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire
Andreas du Bois - Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany
Diana Eccles - Wessex Clinical Genetics Service, Southampton University Hospitals Trust, Southampton, United Kingdom
Svend Aage Engelholm - Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Peter A Fasching - Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Simon A Gayther - Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California
Aleksandra Gentry-Maharaj - Women's Cancer, Institute for Women's Health, University College London, London, United Kingdom
Rosalind M Glasspool - The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Marc T Goodman - Department of Biomedical Sciences, Community and Population Health Research Institute, Cedars-Sinai Medical Center, Los Angeles, California
Jacek Gronwald - Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
Philipp Harter - Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany
Alexander Hein - Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Florian Heitz - Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany
Peter Hillemmanns - Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Niedersachsen, Germany
Claus Høgdall - Department of Gynaecology, Rigshospitalet, University of Copenhagen, Herlev, Denmark
Estrid V S Høgdall - Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
Tomasz Huzarski - Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
Allan Jensen - Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
Sharon E Johnatty - Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, Australia
Audrey Jung - University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Heidelberg, Germany
Beth Y Karlan - Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
Reudiger Klapdor - Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Niedersachsen, Germany
Tomasz Kluz - Clinic of Obstetrics and Gynecology, Institute of Midwifery and Emergency Medicine, Faculty of Medicine, University of Rzeszów, Rzeszów, Poland
Bożena Konopka - Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Susanne Krüger Kjær - Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
Jolanta Kupryjanczyk - Department of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Diether Lambrechts - Department of Oncology, Laboratory for Translational Genetics, Vesalius Research Center, University of Leuven, Leuven, Belgium
Jenny Lester - Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
Jan Lubiński - Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
Douglas A Levine - Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, NYU Langone Medical Center, New York, New York
Lene Lundvall - Department of Gynecology, The Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Valerie McGuire - Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California
Iain A McNeish - Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow, United Kingdom
Usha Menon - Women's Cancer, Institute for Women's Health, University College London, London, United Kingdom
Francesmary Modugno - Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Roberta B Ness - The University of Texas School of Public Health, Houston, Texas
Sandra Orsulic - Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
James Paul - The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Celeste Leigh Pearce - Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California
Tanja Pejovic - Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon
Paul Pharoah - Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom
Susan J Ramus - The Kinghorn Cancer Centre, Garvan Institute of Medical Research, New South Wales, New South Wales, Australia
Joseph Rothstein - Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California
Mary Anne Rossing - Department of Epidemiology, University of Washington, Seattle, Washington
Matthias Rübner - Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Joellen M Schildkraut - Department of Public Health Sciences, The University of Virginia, Charlottesville, Virginia
Barbara Schmalfeldt - Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Ira Schwaab - Praxis für Humangenetik, Wiesbaden, Germany
Nadeem Siddiqui - Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, United Kingdom
Weiva Sieh - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
Piotr Sobiczewski - Department of Gynecologic Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Honglin Song - Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom
Kathryn L Terry - Harvard T. H. Chan School of Public Health, Boston, Massachusetts
Els Van Nieuwenhuysen - Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
Adriaan Vanderstichele - Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
Ignace Vergote - Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
Christine S Walsh - Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
Penelope M Webb - Population Health Department, QIMR Berghofer Medical Research Institute, Herston, Australia
Nicolas Wentzensen - Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland
Alice S Whittemore - Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California
Anna H Wu - Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California
Argyrios Ziogas - Department of Epidemiology, University of California Irvine, Irvine, California
Kunle Odunsi - Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York
Jenny Chang-Claude - University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Heidelberg, Germany
Ellen L Goode - Department of Health Science Research, Mayo Clinic, Rochester, Minnesota
Kirsten B Moysich - Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York. kirsten.moysich@roswellpark.org
Australian Ovarian Cancer Study
Publication Details: Cancer epidemiology, biomarkers & prevention, Vol.26(3), pp.420-424
Date published: 03/2017
Grant note: R01 CA188900 / NCI NIH HHS R01 CA140622 / NCI NIH HHS 10119 / Cancer Research UK R25 CA092049 / NCI NIH HHS P30 CA015083 / NCI NIH HHS R01 CA112523 / NCI NIH HHS R01 CA087538 / NCI NIH HHS P50 CA136393 / NCI NIH HHS R01 CA126841 / NCI NIH HHS 10124 / Cancer Research UK P50 CA159981 / NCI NIH HHS T32 GM008752 / NIGMS NIH HHS P30 CA014089 / NCI NIH HHS G0501974 / Medical Research Council
Academic Unit: Cancer Epidemiology and Health Outcomes
Language: English
Resource Type: Journal article
Identifiers: 991031665969604646